Local
Fortvita Receives Its First Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Source: Town Times

The opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is Fortvita's first European regulatory milestone; if approved, Zybrivo would expand first-line treatment options for eligible patients with lung cancer in Europe
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Town Times



